Sana Biotechnology, Inc. 8-K

What Happened
Sana Biotechnology, Inc. (Sana) filed a Form 8-K on January 14, 2026 (Regulation FD disclosure) to provide an updated corporate presentation that it discussed at the 44th Annual J.P. Morgan Healthcare Conference. The presentation (furnished as Exhibit 99.1) summarizes program and platform updates, including clinical progress for its hypoimmune (HIP) engineered cell therapies and timelines for upcoming programs.

Key Details

• UP421 (primary pancreatic islet cell therapy using Sana’s HIP technology): at 12 months post‑transplant into a patient with type 1 diabetes who received no immunosuppression, the cells “continued to survive, evade immune detection, and function.”
• SC451 (HIP‑modified, iPSC‑derived pancreatic islet cell therapy): Sana says it remains on track to file an IND and begin a Phase 1 trial “as early as this year.”
• SG293 (in vivo CD19‑directed CAR T cell therapy): Sana announced a goal of generating initial human data “as early as this year.”
• The corporate presentation was furnished as Exhibit 99.1 to the 8‑K; the report was signed January 14, 2026 by Aaron M. Grossman (EVP, Chief Legal Officer).

Why It Matters
These disclosures provide concrete clinical updates and timing for near‑term regulatory and data milestones across Sana’s cell-therapy programs. For investors, the reported 12‑month survival and function of UP421 without immunosuppression is a tangible clinical data point, and the stated IND/Phase 1 and initial‑human‑data timelines for SC451 and SG293 establish potential near‑term catalysts. The filing contains no new financial results.